mTOR kinase inhibitor sensitizes T-cell lymphoblastic leukemia for chemotherapy-induced DNA damage via suppressing FANCD2 expression

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Leukemia

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/leu.2013.215PMID 23852546PMCID PMC3947286
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• mTOR regulates DNA damage response through NF-κB-mediated FANCD2 pathway in hematopoietic cells

  2013cited by this paper
• Molecular pathogenesis and clinical management of Fanconi anemia.

  2012cited by this paper
• The PP242 Mammalian Target of Rapamycin (mTOR) Inhibitor Activates Extracellular Signal-regulated Kinase (ERK) in Multiple Myeloma Cells via a Target of Rapamycin Complex 1 (TORC1)/ Eukaryotic Translation Initiation Factor 4E (eIF-4E)/RAF Pathway and Activation Is a Mechanism of Resistance*

  2012cited by this paper
• Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia

  2011cited by this paper
• Reduced VEGF production, angiogenesis, and vascular regrowth contribute to the antitumor properties of dual mTORC1/mTORC2 inhibitors.

  2011cited by this paper
• Pediatric leukemia predisposition syndromes: clues to understanding leukemogenesis.

  2011cited by this paper
• Mammalian Target of Rapamycin (mTOR): Conducting the Cellular Signaling Symphony*

  2010cited by this paper
• The mTOR pathway: a new target in cancer therapy.

  2010cited by this paper
• Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin.

  2009cited by this paper
• A Phase I Study of the Mammalian Target of Rapamycin Inhibitor Sirolimus and MEC Chemotherapy in Relapsed and Refractory Acute Myelogenous Leukemia

  2009cited by this paper
• Defining the role of mTOR in cancer.

  2007cited by this paper
• Antileukemic activity of rapamycin in acute myeloid leukemia.

  2005cited by this paper
• The Akt-mTOR tango and its relevance to cancer.

  2005cited by this paper
• mTOR regulates cell survival after etoposide treatment in primary AML cells.

  2005cited by this paper
• The multifaceted role of mTOR in cellular stress responses.

  2004cited by this paper

• Induction of Triple-Negative Breast Cancer Cell Death and Chemosensitivity Using mTORC2-Directed RNAi Nanomedicine

  2025cites this paper
• Identification of arnicolide C as a novel chemosensitizer to suppress mTOR/E2F1/FANCD2 axis in non‐small cell lung cancer

  2023cites this paper
• Quinacrine-CASIN combination overcomes chemoresistance in human acute lymphoid leukemia

  2021cites this paper
• mTOR pathway and DNA damage response: A therapeutic strategy in cancer therapy.

  2021cites this paper
• Autophagy and the Wnt Signaling Pathway: A Focus on Wnt/β-catenin signaling.

  2020cites this paper
• Inhibitors of the Fanconi anaemia pathway as potential antitumour agents for ovarian cancer

  2020cites this paper
• The associations of single nucleotide polymorphism rs 2295080 in mTOR with cancer risk : an updated meta-analysis

  2019cites this paper
• Inhibition of mTOR downregulates expression of DNA repair proteins and is highly efficient against BRCA2-mutated breast cancer in combination to PARP inhibition

  2018cites this paper
• Clinical Significance of FANCD 2 Gene Expression and its Association with Tumor Progression in Hepatocellular Carcinoma

  2017cites this paper
• Clinical Significance of FANCD2 Gene Expression and its Association with Tumor Progression in Hepatocellular Carcinoma.

  2017cites this paper
• mTORC1 and DNA‐PKcs as novel molecular determinants of sensitivity to Chk1 inhibition

  2016cites this paper
• mTORC1 and -2 Coordinate Transcriptional and Translational Reprogramming in Resistance to DNA Damage and Replicative Stress in Breast Cancer Cells

  2016cites this paper
• mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer

  2015cites this paper
• 1 mTOR inhibitors suppress homologous recombination repair and synergize with PARP inhibitors via regulating SUV 39 H 1 in BRCA-proficient triple-negative breast cancer

  2015cites this paper
• Glutaminolysis and autophagy in cancer

  2015cites this paper
• Advances in the understanding of Fanconi Anemia Complementation Group D2 Protein (FANCD2) in human cancer.

  2015cites this paper
• Mtor-Fanconi Anemia DNA Damage Repair Pathway in Cancer.

  2014influential citation
• TORC2 inhibition may boost DNA-damaging chemotherapy

  2014cites this paper
• TORC2—a new player in genome stability

  2014cites this paper
• Molecularly targeting the PI3K-Akt-mTOR pathway can sensitize cancer cells to radiotherapy and chemotherapy

  2014cites this paper